Plain-English translation of NCT07087054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help reduce flushing episodes and other symptoms of carcinoid syndrome. Carcinoid syndrome is a condition that happens when certain types of tumors release chemicals into your body, causing uncomfortable symptoms like sudden flushing and digestive problems. About 141 adults will participate — some will receive the medication daily, while others will receive a placebo (a dummy pill) to compare how well the treatment works.
Currently, people with carcinoid syndrome have limited treatment options, and some struggle to control their symptoms even with existing medications. This trial is exploring whether this new medication could offer better relief from the disruptive symptoms that affect daily life.
You likely qualify if…
You likely don't qualify if…
You would participate in a screening phase (up to 11 weeks), then be randomly assigned to either take 80 mg once daily or a placebo for 16 weeks while your symptoms are carefully tracked. If the medication appears to help, you can continue in an extended open-label phase for up to 104 additional weeks where everyone receives the active medication. Throughout the study, you'll complete regular visits to report your flushing episodes and other symptoms, and have blood work or other check-ups as needed to monitor your safety.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States